|
|
Sydney 2005: MIP-1a: Osteolytic & Tumour-Promoting Effects in MM Bone Disease
By Babatunde Oyajobi, MD
|
|
|
04.13.05 |
|
Dr. Oyajobi discussed the role of a specific factor, MIP-1, in osteolysis (bone disease) in MM. MIP-1 is a chemokine that is produced by MM cells and is overexpressed in the bone marrow of MM patients. Experimental results showed that MIP-1a stimulates osteoclast formation and bone resorption in vivo. MIP-1a is dependent on specific signaling pathways (RANK) to affect bone resorption. Use of specific antibodies against MIP-1a inhibited development of osteolytic lesions in a mouse model of MM and decreased the activity of osteoclasts. The antibody also reduced the incidence of splenomegaly in myeloma-bearing mice. Data suggest that blocking MIP-1a reduces tumor burden, bone lesions, and splenomegaly.
Back to session summary
|
 related articles
|
|
print